Reintroducing FBXW7 activity or interfering MCL1 and PLK1 restores paclitaxel sensitivity in resistant cells and thus, targeting these substrates may be a valuable adjunct to paclitaxel for the treatment of breast cancer. Here, MCL1 is linked to breast carcinoma.